Investorideas.com - #Cannabis Stock News; Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Division to Begin Human Trials of Its Lead #Cannabis Strain for Pain; @VeritasPharma

Investorideas.com - #Cannabis Stock News; Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Division to Begin Human Trials of Its Lead #Cannabis Strain for Pain; @VeritasPharma

Research
Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto
Rico

Vancouver, B.C. - November 21, 2017
(Investorideas.com Newswire) Veritas Pharma Inc.- Cannabis and Biopharma News
alert -  (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the
"Company") reports  that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.

Investorideas.com - AgriTech Company Sells to Organic and Cannabis Markets

Investorideas.com - AgriTech Company Sells to Organic and Cannabis Markets

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investorideas.com - The Lowdown on Getting High in Canada

Investorideas.com - The Lowdown on Getting High in Canada

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investorideas.com - New Brunswick becomes first province in Canada to fully secure safe supply of cannabis for all its consumers

Investorideas.com - New Brunswick becomes first province in Canada to fully secure safe supply of cannabis for all its consumers

Investorideas.com - Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto Rico to Begin Human Trials of Its Lead #Cannabis Strain for Pain

Investorideas.com - Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto Rico to Begin Human Trials of Its Lead #Cannabis Strain for Pain

Veritas
Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt:
2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.

The
study will be done in two stages to assess the analgesic effects of this lead
strain. The first stage will have an open label design to look at the feasibility
of two doses of CTL-X in 5 subjects while the second stage will use a
randomized, double-blind, crossover design to assess one dose of CTL-X against
a placebo control strain in 16 subjects who will be exposed to various
modalities of acute pain.

Investorideas.com - Isodiol International (CSE:ISOL) (OTC:ISOLF) Acquires Global Rights to produce products under an Innovative Delivery System Patent

Investorideas.com - Isodiol International (CSE:ISOL) (OTC:ISOLF) Acquires Global Rights to produce products under an Innovative Delivery System Patent

Investorideas.com - 420TV To Produce Original Series Featuring Hollywood's Queen Of Cannabis: Expert, Pioneer & Advocate, Dr. Dina

Investorideas.com - 420TV To Produce Original Series Featuring Hollywood's Queen Of Cannabis: Expert, Pioneer & Advocate, Dr. Dina